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Aspirin and Clopidogrel: Lessons from
PCI-CLARITY, COMMIT 
& CHARISMA
Constantinos Stratos, MD 
I N T R O D U C T I O N
Platelet activation plays a critical role both in spontaneous coronary artery throm-
bosis due to atherosclerotic plaque rupture and in thrombotic complications following 
percutaneous coronary intervention (PCI) with coronary artery stenting. Aspirin use 
has been shown to safely reduce ischemic events throughout the spectrum of clinical 
conditions of coronary artery disease (CAD). Therefore, aspirin is part of the standard 
treatment given to patients with CAD, including those undergoing PCI. Despite the 
inhibition of cyclooxygenase by aspirin, however, platelet activation can still occur 
through thromboxane-independent pathways, leading to the aggregation of platelets 
and the formation of thrombin. For that reason, a more potent antiplatelet effect was 
sought by using other agents – thienopyridines (ticlopidine, clopidogrel) and glyco-
protein IIb/IIIa (GpIIb/IIIa) inhibitors, usually in combination with aspirin. Indeed, 
depending on the clinical scenario and the concomitant anticoagulants used, regimens 
combining 2 or more of these antiplatelet agents have resulted in fewer ischemic events 
and sometimes more bleeding events compared with aspirin alone.
Clopidogrel is an adenosine diphosphate (ADP)-receptor antagonist, a class of 
oral antiplatelet agents that block the P2Y12 component of the adenosine diphosphate 
receptor and thus inhibit the activation and aggregation of platelets. It is a potent 
antiplatelet agent that has a synergistic antithrombotic effect when combined with 
aspirin. Clopidogrel alone has been shown to benefit patients with documented symp-
tomatic atherosclerosis (recent myocardial infarction [MI], recent stroke, or established 
peripheral arterial disease). Moreover, clopidogrel added to standard regimen with 
aspirin further reduces the rate of death and ischemic complications in patients who 
have undergone PCI, and in those with unstable angina or MI without ST-segment 
elevation (non-STE ACS). However, the effects of the addition of clopidogrel in pa-
tients who have MI with ST-segment elevation (STEMI) and who are receiving or 
not a standard fibrinolytic regimen, including aspirin, and/or who may undergo PCI 
remain unclear. The pretreatment with a loading dose and the timing of clopidogrel 
administration in the setting of the STEMI with or without subsequent PCI also are 
issues an answer will oblige. In addition, the incremental value of long-term dual an-
tiplateled therapy, validated in the settings of coronary stenting and non-STE ACS for 
a mid-term period of 9 to 12 months, is unknown in the broader population of patients 
with symptomatic or asymptomatic atherothrombosis. PCI-CLARITY [1], COMMIT 
[2] and CHARISMA [3] are studies that address some of these issues.
CARDIOLOGY UPDATE 2006
Assistant Director, Cardiology 
Department, Henri Dunant Hospital, 
Athens, Greece
HOSPITAL CHRONICLES 2006, SUPPLEMENT: 9–17
Address for correspondence:
Constantinos Stratos, MD 
Assistant Director, Cardiology 
Department, Henri Dunant Hospital, 
Athens, Greece
E-mail: cstratos@otenet.gr
10
HOSPITAL CHRONICLES, SUPPLEMENT 2006 ASPIRIN AND CLOPIDOGREL: LESSONS FROM PCI-CLARITY, COMMIT & CHARISMA
11
D U A L  A N T I P L A T E L E T  T H E R A P Y  W I T H  
C L O P I D O G R E L  A N D  A S P I R I N  I N  T H E  
S E T T I N G  O F  S T E M I
In patients with STEMI, rupture of an atherosclerotic 
plaque leads to platelet adhesion, activation, and aggregation, 
with subsequent vessel occlusion due to thrombus formation. 
In these circumstances, the most effective pharmacologic re-
perfusion regimen is concurrent fibrinolytic therapy and plate-
let inhibition. The marked benefit of such a combination was 
first established in the Second International Study of Infarct 
Survival (ISIS-2), in which 35-day mortality among patients 
with suspected MI was 13.2 percent for those receiving neither 
streptokinase nor aspirin, approximately 10.5 percent for those 
given one or the other, and 8.0 percent for those receiving both 
agents [4]. Subsequently, aspirin serves a foundational role in 
fibrinolytic therapy regimens.
Although aspirin, administered with or without fibrino-
lytic therapy, reduces mortality among patients with MI, it 
has limitations. First, it is a relatively weak antiplatelet agent. 
It irreversibly inhibits platelet cyclooxygenase, thereby block-
ing the synthesis of thromboxane A2, a powerful promoter 
of platelet activation, but it exerts no effect on thromboxane-
independent mediators of platelet activation, such as ADP, 
thrombin, or serotonin. Second, in up to 30% of persons with 
coronary artery disease, the condition is relatively resistant or 
unresponsive to aspirin.
All mediators of platelet activation cause conformational 
changes in the platelet-surface GpIIb/IIIa receptor, allowing 
it to bind to circulating fibrinogen and to form platelet–fibrin 
aggregates. As a result, inhibitors of the GpIIb/IIIa recep-
tor are the most potent antiplatelet agents, since they block 
the final common pathway for platelet aggregation. In pilot 
studies, patients who had STEMI who were given aspirin and 
fibrinolytic therapy had earlier and more complete coronary 
arterial reperfusion when a GpIIb/IIIa inhibitor was admin-
istered concomitantly than when it was not. Subsequently, 
several trials showed that concomitant administration of 
reduced-dose fibrinolytic therapy, aspirin, and a GpIIb/IIIa 
decreased the incidence of in-hospital reinfarction by 1 to 2 
percent as compared with full-dose fibrinolytic therapy and 
aspirin. However, this modest reduction in the incidence 
of reinfarction was offset by a concomitant increase in the 
incidence of nonintracranial bleeding. In short, the addition 
of very potent antiplatelet therapy (in the form of GpIIb/IIIa 
inhibitors) to fibrinolytic therapy (even at a reduced dose) 
lessened the risks of reocclusion and recurrent infarction af-
ter successful reperfusion, but it did so at the expense of an 
increase in the frequency of bleeding complications.
PCI in the setting of STEMI has been emerged as a 
very effective and relatively safe therapy. However, access to 
such an interventional therapy is not available in most cases. 
Moreover, the addition of very potent adjunctive antiplatelet 
therapy seems to be necessary, and has been shown to benefit 
patients with ACS who undergo PCI, but it increases the risk 
of severe hemorrhagic complications.
Clopidogrel is a more potent platelet inhibitor than aspirin, 
but it is less potent than the GpIIb/IIIa inhibitors. As is the 
case with aspirin, the response of platelets to clopidogrel is 
heterogeneous, and resistance to therapy has been reported. In 
patients with stable angina, dual therapy with aspirin and clopi-
dogrel exerts greater inhibitory effects on platelet activation 
and aggregation than therapy with either agent alone. In pa-
tients with non-STE ACS, an aspirin–clopidogrel combination 
improved cardiovascular outcomes, as compared with aspirin 
alone [5,6]. Unfortunately, those treated with combination 
therapy had a greater risk of bleeding than those treated with 
aspirin alone, and this finding was particularly noteworthy 
among those in whom clopidogrel was discontinued within 
five days before coronary-artery bypass grafting. There was 
no excess rate of fatal bleeding, bleeding requiring surgical 
intervention, or hemorrhagic stroke. The excess major bleed-
ing episodes were gastrointestinal hemorrhages and bleeding 
at the sites of arterial punctures [5].
In conclusion, because many patients are resistant to the 
effects of a single oral antiplatelet agent, therapy with multiple 
agents with different mechanisms of action is conceptually 
attractive, provided that it can be administered without an 
increased risk of bleeding. The combination of clopidogrel 
and aspirin has been shown to improve the outcome without 
any significant increase in the rate of major life-threatening 
or disabling bleedings in a very wide range of patients with 
CAD, including those undergoing PCI [5-7]. In contrast, 
the addition of the very potent GpIIb/IIIa inhibitors to the 
standard regimen including aspirin improves the outcome 
too, but increases the risk for major bleeding complications. 
Therefore, the combination of clopidogrel and aspirin should 
be investigated in the setting of management of patients with 
STEMI.
T H E  P C I - C L A R I T Y  S T U D Y
On March 2005, the Clopidogrel as Adjunctive Reper-
fusion Therapy (CLARITY)-Thrombolysis in Myocardial 
Infarction (TIMI) 28 investigators reported their findings 
from 3491 STEMI patients receiving fibrinolytic therapy, 
including aspirin, who were randomized to receive a 300-mg 
loading dose and then a 75-mg daily dose of clopidogrel or 
placebo [8]. Patients were enrolled mainly in Western Europe 
and North America. The average time from symptom onset to 
fibrinolytic administration was just under 3 h and more than 
two-thirds of patients received a fibrin-specific lytic, with the 
rest receiving streptokinase. Patients underwent coronary an-
giography 2–8 days after the start of study medication (median 
of 3.5 days). Of these patients, 57.2% from the clopidogrel 
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group and 56.6% from the placebo group underwent PCI 
during the index hospitalization and formed the basis for 
PCI-CLARITY [1]. The decision to perform PCI was at the 
operator’s direction. Moreover, all patients undergoing coro-
nary stent placement received an open-label 300-mg loading 
dose of clopidogrel after the initial angiogram, followed by a 
daily dose of 75 mg. The primary endpoint was an occluded 
infarct-related artery or death or MI before angiography, and 
patients were also followed for 30 days for clinical events. The 
CLARITY-TIMI 28 study demonstrated the benefit of adding 
clopidogrel to aspirin and fibrinolytic therapy for STEMI. The 
treatment improved the patency rate of the infarct-related 
artery and reduced the odds of the composite primary efficacy 
end point of an occluded infarct-related artery or death or 
recurrent MI by the time of angiography, a median of 3.5 days 
after enrollment. Moreover, by 30 days, the treatment led to a 
significant reduction in the ischemic complications. The study 
was not specifically powered to assess individual clinical end 
points at 30 days, but cardiac mortality rates appeared similar 
between the clopidogrel and placebo groups (4.4% vs. 4.5%), 
even though the rate of reinfarction was lower with clopidogrel 
(4.1% vs. 5.9%; OR, 0.69; P = 0.02). The respective rates 
of major bleeding complications were similar between the 2 
groups (1.9% vs. 1.7%). Weighing the observations from the 
CLARITY-TIMI 28 and abciximab-STEMI meta-analysis [9], 
it can be concluded that the addition of either abciximab or 
clopidogrel to the aspirin component of thrombolytic therapy 
reduces the 30-day occurrence of reinfarction by roughly 
one-third but does not affect mortality. In these studies, the 
addition of abciximab significantly increased major bleeding 
complications while the addition of clopidogrel does not [8,9]. 
However, in the most recent ISAR-REACT 2 trial, a triple 
antiplatelet therapy (clopidogrel, including loading dose of 600 
mg, aspirin, abciximab) in patients undergoing PCI did not 
significantly increase the  risk of major and minor bleeding 
as well as need for transfusion [10].
Clopidogrel also has a well-established record of reduc-
ing ischemic events without increasing bleeding complica-
tions when used for PCI. Unlike intravenously administered 
GpIIb/IIIa inhibitors, which are effective in minutes, clopi-
dogrel requires hours to days after oral administration to be-
come effective, according to the initial dose. Several post-hoc 
analyses from large-scale PCI trials showed patients receiving 
clopidogrel hours to days before, rather than at the time of 
PCI, experienced substantially fewer periprocedural ischemic 
events. The first prospective study of clopidogrel pretreatment, 
CREDO [7], randomized 2,116 patients to 300-mg pretreat-
ment versus no pretreatment and observed that clopidogrel at 
this loading dose needed to be given at least 15 hours prior to 
PCI to be significantly effective and 24 hours preprocedure 
to be maximally effective. For patients scheduled in advance 
for cardiac catheterization and possible PCI, pretreatment 
with clopidogrel at least a day before the procedure became 
intuitive. On the other hand, because the biological effect of 
clopidogrel lasts for days, many physicians have been reluctant 
to pretreat patients until coronary angiography has excluded 
their need for surgical revascularization. This concern was 
borne out in the CURE trial [5], in which patients with ACS 
randomized to receive clopidogrel and undergoing surgical 
revascularization within 5 days of receiving clopidogrel had a 
53% increased risk for major bleeding compared with similar 
patients receiving placebo.
PCI-CLARITY [1] study addressed several important 
issues regarding clopidogrel pretreatment before PCI among 
STEMI patients. It was a prespecified test of the hypothesis 
that in patients undergoing PCI after initial pharmacological 
therapy for STEMI, clopidogrel pretreatment hours to days 
before PCI is superior to clopidogrel treatment initiated at the 
time of PCI in preventing major adverse cardiovascular events. 
The study demonstrated a substantial reduction in the compos-
ite end point of cardiovascular death, reinfarction, or stroke 
from PCI to 30 days among those pretreated with clopidogrel 
(3.6% vs. 6.2%; OR, 0.54 [95% CI, 0.35-0.85]; P = 0.008). 
In addition, clopidogrel pretreatment was associated with a 
reduced odds of reinfarction or stroke prior to PCI (4.0% vs. 
6.2%; OR, 0.62 [95% CI, 0.40-0.95]; P = 0.03). This benefit 
was seen in patients with STEMI treated with fibrinolysis who 
subsequently underwent PCI on average 3 days later, but with 
a consistent benefit regardless of the time from initiation of 
pretreatment to PCI. Moreover, benefits were seen regardless of 
whether patients received a GpIIb/IIIa inhibitor at the time of 
PCI or whether patients received a loading dose of open-label 
clopidogrel at the time of PCI. Major bleeding events occurred 
at a similar frequency between the groups (0.5% vs. 1.1%, 
respectively; P = 0.21). In conclusion, clopidogrel pretreatment 
significantly reduces the incidence of cardiovascular death or 
ischemic complications both before and after PCI and without 
a significant increase in major or minor bleeding. These data 
add further support to the early use of clopidogrel in STEMI 
and the strategy of routine clopidogrel pretreatment in patients 
undergoing PCI.
Several points from CLARITY and PCI-CLARITY are 
worthy of mention. First, few patients presenting with STEMI 
undergo a CABG surgery during the index hospitalization, 
so little concern should be given regarding early clopidogrel 
administration and the subsequent need for urgent surgery 
(only 6% of patients in CLARITY underwent CABG surgery). 
Second, patients who undergo PCI in the setting of an ACS 
(non-STEMI and STEMI) are at particularly high risk for 
periprocedural MI. As such, it is not surprising that the rela-
tive risk reduction in ischemic events provided by clopidogrel 
was twice as high among CLARITY patients who underwent 
PCI than those who did not. Specifically, patients receiving 
clopidogrel pretreatment before angiography and who were 
treated medically or underwent CABG surgery had approxi-
mately a 17% risk reduction for reinfarction at 30 days (2.0% 
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from less than 6 hours to 8 days and showed a consistent benefit 
of clopidogrel pretreatment across this range of pretreatment 
durations. Of note, although the maximal effect of clopidogrel 
on platelet inhibition may not occur until 6 or more hours after a 
300-mg loading dose, some degree of platelet inhibition can be 
measured as early as 90 minutes. Prior studies have shown that 
the degree of platelet inhibition at the time of PCI is strongly 
related to the likelihood of major adverse cardiovascular events 
following PCI. PCI-CLARITY suggests that in the setting of 
an ACS with heightened platelet activation and PCI causing 
immediate and further platelet activation, even relatively 
brief durations of pretreatment with clopidogrel before PCI 
may translate into improved patient outcomes. Third, PCI-
CLARITY showed a benefit with clopidogrel pretreatment 
regardless of whether a standard loading dose of clopidogrel 
was administered in the cardiac catheterization laboratory 
at the time of PCI. Fourth, the study showed a benefit with 
clopidogrel pretreatment regardless of GpIIb/IIIa inhibitor 
use peri-PCI in patients with ACS. This finding is supported 
by results from nonrandomized comparisons in registries and 
in the TARGET and REPLACE trials, and builds on a similar 
observation made in the setting of elective PCI in CREDO [7] 
and non-STE ACS in PCI-CURE.
Taken together, the PCI-CURE, CREDO, and PCI-
CLARITY, demonstrate a clear and consistent benefit with 
clopidogrel pretreatment for PCI across the spectrum from 
stable coronary artery disease to STEMI, and regardless of 
patient demographics or the use of a GpIIb/IIIa inhibitor at 
the time of PCI. The significant reduction in adverse cardio-
vascular events before PCI suggests that a strategy of clopi-
dogrel pretreatment should be initiated as soon as possible. 
Accordingly, even if clopidogrel is not given at presentation, 
once the decision is made to proceed with angiography, and 
hence possible PCI, initiation of pretreatment will maximize 
the benefit.
In the PCI-CLARITY study, like in PCI-CURE, the 
event curves following PCI continued to diverge over time 
despite almost all patients in both treatment groups receiv-
ing open-label clopidogrel following PCI. This observation 
suggests that the beneficial effect of clopidogrel may extend 
beyond just prevention of platelet aggregation and myocyte 
necrosis during the procedure. By blocking the P2Y12 recep-
tor, clopidogrel inhibits platelet activation and thus may have 
more widespread effects on endothelial cells, leukocytes, 
and inflammation. For example, clopidogrel has been shown 
to blunt expression of both P-selectin and CD40 ligand, the 
former of which contributes to platelet-leukocyte aggregation 
and the latter of which can trigger an inflammatory response 
in endothelial cells. In addition, thienopyridine pretreatment 
has been shown to attenuate the rise in CRP immediately after 
PCI and to decrease the need for target vessel revasculariza-
tion over 1 year.
Finally, like any study, PCI-CLARITY has limitations, 
vs. 2.4%) compared with a 35% reduction among similarly 
treated patients who underwent PCI (5.9% vs. 8.9%). In PCI-
CLARITY, roughly two thirds of the reinfarctions occurred 
in the 3.1 days (median) before PCI, with the remainder oc-
curring during or soon after revascularization. Importantly, 
clopidogrel treatment provided a consistent level of protection 
against reinfarction during both of these intervals (OR, 0.60). A 
similar bimodal occurrence of events and protection has been 
observed among non-STEMI ACS patients treated before and 
during PCI with GpIIb/IIIa inhibitors.
A third important point concerns the remaining un-
certainty about the optimal dose and timing of clopidogrel 
administration. The 300-mg loading dose used in CLARITY 
is established to be effective in the PCI-CURE and CREDO 
[7] trials, yet other studies suggest the 300-mg loading dose is 
incompletely effective or requires a longer minimum interval 
for peak effect than noted in PCI-CLARITY. ARMYDA-2 
study showed that a 600-mg loading dose of clopidogrel 4 to 
8 hours before PCI safely and more effectively reduced the 
occurrence of periprocedural infarctions than a 300-mg load-
ing dose. Yet, even the 600-mg dose may not be optimal, as 
suggested by data from the recently presented ALBION trial, 
in which a 900-mg loading dose provided an even greater and 
more rapid antiplatelet effect than 600 mg as determined by 
several ex vivo measure of platelet function. Patients receiv-
ing long-term clopidogrel therapy may also benefit from an 
additional loading dose. Indeed, a recent study demonstrated 
that a 600-mg loading dose of clopidogrel given to patients 
already receiving long-term (>1 month) clopidogrel therapy 
was able to achieve additional aggregation inhibition beyond 
that provided by the daily dose. The PCI-CLARITY study 
provided an opportunity to assess some of these concepts clini-
cally since it was recommended that all patients undergoing 
coronary stent placement receive an open-label 300-mg loading 
dose of clopidogrel after the initial angiogram. Patients who 
were randomized to receive a 300-mg loading dose and then 
a 75-mg daily dose of clopidogrel at enrollment (pretreatment) 
and who subsequently received an additional 300-mg dose 
at the time of PCI (retreatment) had the lowest rate of death, 
reinfarction, and stroke following PCI to 30-day follow-up 
compared with those who received a clopidogrel loading dose 
only at enrollment, only during PCI, or at neither time.
The PCI-CURE [6] and CREDO [7] provided important 
data on the value of clopidogrel pretreatment in patients with 
non-STE ACS undergoing PCI and in patients undergoing 
planned, elective PCI, respectively. The PCI-CLARITY study 
builds on these prior studies in several important ways. First, 
PCI-CLARITY studied patients with STEMI and showed a 
benefit with clopidogrel pretreatment in these patients who are 
at the highest risk for early recurrent ischemic events. Clopido-
grel thus appears to be an important component to include in a 
pharmacoinvasive approach to patients with STEMI. Second, 
this study evaluated a broad range of durations of pretreatment 
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particularly since PCI was not randomized. The trial excluded 
many patient groups known to be at particularly high risk for 
death, reinfarction, or major bleeding events such as patients 
older than 75 years, those with prior CABG surgery, prior 
intracranial hemorrhage or non-hemorrhagic stroke, or with 
a creatinine level higher than 2.5 mg/dL (221 ìmol/L). While 
the investigators carefully performed propensity analysis to 
correct for selection bias for undergoing PCI, it is possible that 
residual confounding factors were present. For example, undis-
cerned factors may exist that explain why patients receiving a 
GpIIb/IIIa inhibitor had event rates higher than patients not 
receiving GpIIb/IIIa inhibitors or why one fourth of patients 
did not receive open-label clopidogrel loading at the time of 
PCI. However, despite the existing limitations, PCI-CLAR-
ITY provides important data, and application of the study 
findings seems straightforward — patients receiving thrombo-
lytic therapy for STEMI should also receive a 300-mg loading 
dose of clopidogrel followed by 75 mg daily. Additionally, clini-
cians should consider giving 600 mg of clopidogrel as a loading 
dose, even though this approach has not been formally tested 
with thrombolytic therapy. So far, no major safety concerns 
have emerged with 600- or 900-mg loading doses. Finally, all 
patients not receiving a loading dose within several days of 
angiography should be considered for clopidogrel retreatment 
(i.e., repeat loading dose) at the time of PCI.
In conclusion, PCI-CLARITY found that in high-risk pa-
tients with STEMI treated with fibrinolytic therapy, a strategy 
of clopidogrel pretreatment significantly reduced the incidence 
of cardiovascular death and ischemic complications both before 
and after PCI without a significant increase in major or minor 
bleeding. These data add further support to the early use of 
clopidogrel in STEMI and the broader strategy of clopidogrel 
pretreatment in patients undergoing PCI.
T H E  C O M M I T  S T U D Y
Clopidogrel and Metoprolol in Myocardial Infarction Trial 
(COMMIT) [2] is the second of the two trials published last 
year that defined the role of combined regimen of clopido-
grel and aspirin in the setting of STEMI [2,8]. COMMIT 
addressed the net effects on mortality and major morbidity of 
adding clopidogrel to aspirin in this setting. The study enrolled 
nearly 46,000 patients who presented within 24 hours after the 
onset of a suspected acute MI and were randomly assigned 
to receive clopidogrel (75 mg daily) or placebo in addition to 
aspirin. Treatment was to continue until discharge or up to 
4 weeks in hospital (mean 15 days in survivors). There were 
several differences between COMMIT and the above men-
tioned CLARITY-TIMI 28. COMMIT was done exclusively 
in China, there was no upper age limit (26% of patients aged 
70 years or older), and the average time from symptom onset 
to presentation was a little over 10 hours. Only half of patients 
received fibrinolytic therapy on presentation (urokinase), and 
clopidogrel was administered as 75 mg daily, without a loading 
dose. Fewer than 5% of patients went on to have PCI. The 
two prespecified co-primary outcomes were: (1) the combina-
tion of death, reinfarction, or stroke; and (2) death from any 
cause during the scheduled treatment period. In short, this 
large randomized trial showed that addition of clopidogrel to 
aspirin reduces mortality and major morbidity in a wide range 
of patients with suspected acute MI, and these benefits seem 
to be largely independent of, and hence additional to, those of 
other standard treatments such as fibrinolytic and anticoagu-
lant therapy. The findings also show that such treatment is safe, 
with no apparent increase in life-threatening bleedings even 
when given with fibrinolytic therapy, or to older patients.
Several points from COMMIT are worth highlighting. To 
begin, a fascinating and unexpected observation was that the 
benefit of clopidogrel had emerged as early as the first day after 
a simple first dose of 75 mg without an initial loading dose. 
Indeed, some of the clinical benefit of clopidogrel seemed 
to emerge rapidly, with a marginally significant 12% (SE 6; 
P = 0.05) proportional reduction in death, reinfarction, or 
stroke on day 0 (i.e., within an average of 12 hours of starting 
treatment) and a somewhat more significant 11% (99% CI 
0–20%, P = 0.01) benefit when the results on days 0 and 1 
were combined. Although it generally takes several days rather 
than hours for clopidogrel to reach steady-state antiplatelet 
effects without an initial loading dose, partial antiplatelet ef-
fects do emerge within a few hours after administering 75 mg 
clopidogrel orally. One may speculate that even such modest 
degrees of platelet inhibition translate into a clinical benefit in 
the critical setting of acute MI or that the clinical benefit was 
in a subset of clopidogrel hyper-responders. The addition of 
an initial loading dose of clopidogrel could, however, produce 
more rapid antithrombotic effects. Indeed, in the CLARITY-
TIMI 28 trial among 3,491 STEMI patients given fibrinolytic 
therapy plus aspirin, a 300-mg loading dose of clopidogrel, 
followed then by 75 mg once daily, was associated with a sig-
nificant reduction in the rate of the composite end point of 
an occluded infarct-related artery on angiography or death 
or MI before angiography (reduction by 31%, P <0.001), and 
improved all angiographic measurements at a median of 3.5 
days. Specifically, this treatment with clopidogrel decreased 
the rate of finding an occluded infarct-related artery (41% 
reduction in the odds, P < 0.001) and the rate of recurrent 
MI (30% reduction in the odds, P = 0.08), and increased the 
odds of achieving optimal epicardial flow by 36% (P <0.001) 
and the odds of achieving optimal myocardial reperfusion by 
21% (P = 0.008). Likewise, in the CURE trial among 12,562 
patients with non-STE ACS given aspirin, an initial 300 mg 
loading dose of clopidogrel was associated with a 20% pro-
portional reduction in the risk of major vascular events within 
24 hours of the initiation of treatment, although this early 
trend was also not significant. Even higher loading doses of 
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clopidogrel could produce even greater antiplatelet effects 
more rapidly, although the bleeding risk would need to be 
monitored, especially in older patients who are at somewhat 
greater risk of bleeding, but also at somewhat greater risk of 
an occlusive vascular event.
A second important point concerns the remaining uncer-
tainty about the net effect on mortality of adding clopidogrel 
to aspirin. Previous studies, such as the CURE in patients 
with non-STE ACS and the CLARITY-TIMI 28 in patients 
with STEMI, showed a significant reduction in the rate of the 
composite end point or in the rate of recurrent ischemia or 
reinfarction but failed to show any clear reduction in the rate 
of death from cardiovascular causes. Specifically, CLARITY-
TIMI 28 showed that clopidogrel had the greatest effect on the 
rate of an occluded infarct-related artery (reducing it from 18.4 
percent to 11.7 percent; 41% reduction in the odds; P <0.001), 
but it had no significant effect on the rate of death from any 
cause. However, these studies were not powered to detect a 
survival benefit. In COMMIT, clopidogrel significantly re-
duced the odds of the composite of death, MI, or stroke, and, 
perhaps most impressively, mortality alone. These data show 
the first change in pharmacological reperfusion therapy for 
STEMI in over a decade to achieve a mortality benefit. Al-
though fibrinolytics help open an occluded artery, reocclusion 
remains a significant problem. The additive antiplatelet effect 
of clopidogrel on top of aspirin may help shift the balance in 
favour of sustained reperfusion rather than reocclusion. One 
may speculate that such a preservation of the patency could 
have led to the translation of the angiographic benefit into an 
immediate reduction in mortality. Results from CLARITY-
TIMI 28 and COMMIT together provide additional validation 
of the open-artery hypothesis.
Finally, it is reassuring that there was no excess in either 
major bleeding or intracranial hemorrhage in either COM-
MIT or CLARITY-TIMI 28, by contrast with other attempts 
to improve reperfusion in acute MI such as the GUSTO V 
trial. However, it must be noted that there are safety data on 
clopidogrel in the elderly receiving lytic therapy only in the 
absence of a loading dose.
In terms of implications of COMMIT for clinical practice, 
adding clopidogrel 75 mg daily over a standard therapy for 
acute STEMI including aspirin, approximately 10 deaths, 
reinfarctions, or strokes would be prevented for every 1000 
patients treated for 2 weeks. Moreover, daily aspirin prevents 
another 40 deaths, nonfatal reinfarctions, or strokes per 1000 
patients with suspected acute STEMI treated for one at lest 
month, with these early benefits persisting for at least 10 years. 
Consequently, compared with no antiplatelet treatment, it can 
be inferred that the combination of clopidogrel plus aspirin 
prevents an average of about 50 major vascular events per 1000 
treated for just a few weeks soon after the onset of acute MI. 
However, a more rapid and more potent antiplatelet therapy 
with a loading dose of clopidogrel, the use of a fibrin-specific 
fibrinolytic agent instead of the non-specific urokinase, and a 
more prolonged use of the combined antiplatelet regimen after 
acute MI would produce even greater absolute benefits.
In summary, building on the background of aspirin, dual 
antiplatelet therapy, now with the addition of clopidogrel to 
aspirin, represents a major advance in the care of patients 
with acute STEMI, with clear benefit across a broad range of 
patient demographics and practice patterns.
L O N G - T E R M  D U A L  A N T I P L A T E L E T  
T H E R A P Y  W I T H  C L O P I D O G R E L  
A N D  A S P I R I N
Platelets have been shown to play a central role in the 
pathogenesis of atherothrombotic process. Low-dose aspirin 
has been shown to reduce ischemic outcomes in patients above 
a certain risk threshold. Therefore, antiplatelet therapy with 
aspirin has earned its rightful place as a cornerstone of treat-
ment for reducing cardiovascular events in patients with es-
tablished vascular disease. However, aspirin alone in many in-
stances is not sufficient to prevent ischemic events in patients at 
high risk, because it inhibits only the cyclooxygenase pathway, 
leaving other powerful thromboxane-independent mediators 
of platelet activation unaffected, and because in up to 30% of 
persons, the condition is relatively resistant or unresponsive 
to aspirin. Clopidogrel, an ADP P2Y12-receptor antagonist, is 
another potent antiplatelet agent. As monotherapy, clopidogrel 
has been shown to be superior to aspirin alone in reducing 
the risk of ischemic stroke, MI, or death from vascular causes 
in patients with established vascular  disease [11]. However, 
there is debate as to whether P2Y12-receptor blockade provide 
uniform benefit among patients with vascular disease. For that 
reason, a more consistent and potent antiplatelet effect was 
sought. Thereafter, dual antiplatelet therapy with clopidogrel 
plus aspirin has been found to be superior to monotherapy 
with either drug alone. Since CAPRIE [11], four large clinical 
trials have added to the body of evidence that supports the 
use of dual antiplatelet therapy in patients with ACS and in 
those undergoing PCI [2,5,7,8]. However, these studies were 
limited into the setting of symptomatic CAD, which represents 
only a part of the entire burden of the atherosclerotic vascular 
disease. Furthermore, the value of dual antiplatelet therapy 
has been evaluated only for a very short- up to a mid-term 
period of 9 to 12 months. Accordingly, the logical next step 
was the evaluation of the potential role of the long-term dual 
antiplatelet therapy in a broad population of patients with es-
tablished vascular disease (documented history of established 
CAD, cerebrovascular disease, or peripheral arterial disease) 
or multiple cardiovascular risk factors.
The Clopidogrel for High Atherothrombotic Risk 
and Ischemic Stabilization, Management, and Avoidance 
(CHARISMA) trial, a prospective, multicenter, random-
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ized, double-blind, placebo-controlled study, tested the 
hypothesis that long-term treatment with a combination of 
clopidogrel plus aspirin may provide greater protection against 
cardiovascular events than aspirin alone in a broad population 
of patients at high risk [3]. Therefore, the trial was probing 
uncharted territory in determining whether long-term dual 
antiplatelet therapy would be of incremental clinical value in 
patients with vascular disease without an acute manifestation 
of injury. The study enrolled 15,603 patients with either clini-
cally evident cardiovascular disease or multiple risk factors 
to receive clopidogrel (75 mg per day) plus low-dose aspirin 
(75 to 162 mg per day) or placebo plus low-dose aspirin and 
followed them for a median of 28 months. The primary ef-
ficacy end point was a composite of MI, stroke, or death from 
cardiovascular causes.
As regards the whole study population, there was no 
significant benefit associated with clopidogrel plus aspirin as 
compared with placebo plus aspirin in reducing the incidence 
of the primary end point of MI, stroke, or death from cardio-
vascular causes (6.8% vs. 7.3%, P = 0.22). There was a mod-
erate, though significant, benefit in reducing the secondary 
composite end point of MI, stroke, death from cardiovascular 
causes, or hospitalization for unstable angina, transient isch-
emic attack, or revascularization (16.7% vs. 17.9%, absolute 
reduction 1.2%; P = 0.04). This finding was mainly due to 
the significant reduction of the hospitalizations (11.1% vs. 
12.3%, absolute reduction 1.2%; P = 0.02). The rate of severe 
bleeding was not significantly greater with clopidogrel than 
with placebo, but a trend prompting concern was noted (1.7% 
vs. 1.3%; P=0.09), and clopidogrel was associated with a sig-
nificant increase in the rate of moderate bleeding (2.1% vs. 
1.3%, P < 0.001). A total of 94 secondary ischemic end points 
(mainly hospitalizations) were prevented with clopidogrel, at 
a cost of 93 moderate or severe bleeding events.
A subgroup analysis suggested that clopidogrel was benefi-
cial with respect to the primary efficacy end point in patients 
who were classified as symptomatic (6.9% vs. 7.9%, P=0.046). 
However, this observation should be interpreted with caution, 
but not just because the interaction term was only marginally 
significant and not adjusted for multiple analyses. Moreover, 
it must be noted that the characteristics that differentiate 
patients in this subgroup are not sufficiently distinct. As 
reported, some of the patients termed “asymptomatic” had 
major cardiovascular events, and one would assume that a 
large proportion of the patients termed “symptomatic” also 
had multiple risk factors. Clopidogrel had no significant ef-
fect on death from cardiovascular causes in this subgroup. As 
regards the bleedings, the risk of moderate or severe bleed-
ing in symptomatic patients was greater with clopidogrel than 
with placebo, although there was no significant increase in 
intracranial or fatal bleeding.
On the other hand, the risk associated with dual anti-
platelet therapy in the asymptomatic group (only multiple 
cardiovascular risk factors) was not anticipated. Although 
the difference in the rates of primary end point between 
clopidogrel and placebo was not significant (6.6% vs. 5.5%, 
P = 0.20), there were excess fatalities and a heightened risk of 
bleeding complications in this group. There was a significant 
increase in the rate of death from all causes among the patients 
assigned to clopidogrel plus aspirin as compared with those 
assigned to placebo plus aspirin (5.4% vs. 3.8%, P = 0.04) as 
well as an increase in the rate of death from cardiovascular 
causes among those assigned to clopidogrel (3.9% vs. 2.2%, 
respectively; P = 0.01). There is no reasonable and convinc-
ing interpretation of this unexpected finding, at present. It is 
possible that established vascular disease represents a crude 
proxy for hyperactive platelets. If this concept is accepted, 
dual antiplatelet therapy would be anticipated to be associ-
ated with greater efficacy and a lower rate of bleeding in the 
subgroup of symptomatic patients. However, reduced basal 
platelet activity in asymptomatic patients would be expected 
to be a liability, increasing the risk of bleeding complications, 
including possible hemorrhage into an arterial plaque. What-
ever the explanation, it appears that until proven otherwise, 
clinicians should avoid dual antiplatelet therapy in patients 
without established vascular disease. Moreover, the issue of 
whether dual antiplatelet therapy is beneficial in more specific 
subgroups of the population of patients with atherothrombotic 
disease or risk will require further study.
In terms of hemorrhagic complications in the subgroup 
analysis, there were no significant differences in the rates of 
severe bleeding between clopidogrel and placebo both among 
symptomatic (1.6% vs. 1.4%, P = 0.39) and among asymptom-
atic patients (2.0% vs. 1.2%, P = 0.07), but a noticeable trend 
in favor of placebo was observed in both subgroups. Likewise, 
the rate of moderate bleeding among asymptomatic patients 
trended to be greater with clopidogrel than with placebo, but 
the difference was not significant (2.2% vs. 1.4%, P = 0.08). 
In contrast, in the symptomatic group, there was a significant 
increase in the rate of moderate bleeding among patients as-
signed to clopidogrel as compared with those assigned to 
placebo (2.1% vs. 1.3%, P < 0.001).
In conclusion, the combination of clopidogrel plus aspi-
rin was not significantly more effective than aspirin alone in 
reducing the rate of myocardial infarction, stroke, or death 
from cardiovascular causes among patients with stable car-
diovascular disease or multiple cardiovascular risk factors. 
Furthermore, the risk of moderate-to-severe bleeding was 
increased. CHARISMA trial does not support the use of 
dual antiplatelet therapy across the broad population tested. 
There was a potential benefit in symptomatic patients (those 
with established vascular disease); this finding requires further 
study. Data on mortality rates suggest that dual antiplatelet 
therapy should not be used in patients without a history of 
established vascular disease.
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S U M M A R Y
PCI-CLARITY [1] and COMMIT [2] addressed the 
role of adding clopidogrel to the standard regimen for acute 
STEMI including aspirin. The PCI-CLARITY study was a 
prospectively planned analysis of the 1863 patients undergo-
ing PCI after mandated angiography in CLARITY–TIMI 
28, a randomized, double-blind, placebo-controlled trial of 
clopidogrel in patients receiving fibrinolytics for STEMI. 
Patients received aspirin and were randomized to receive 
either clopidogrel (300-mg loading dose followed by 75 mg 
once daily) or placebo initiated with fibrinolysis and given 
until coronary angiography, which was performed 2 to 8 
days (median, 3.5 days) after initiation of the study drug. For 
patients undergoing coronary artery stenting, it was recom-
mended that open-label clopidogrel (including a loading dose) 
be administered after the diagnostic angiogram. It must be 
noted that all PCI-CLARITY patients received fibrinolytics 
and aspirin, approximately 50% of them randomized to re-
ceive clopidogrel and 50% to receive placebo from the time of 
initial presentation until angiography, and nearly all of them 
received an open-label clopidogrel (including a loading dose) 
after angiography and underwent coronary stenting. In addi-
tion, patients were enrolled mainly in Western Europe and 
North America, and the upper age limit was 75 years. This 
study addressed the hypothesis that in patients undergoing PCI 
after initial pharmacological therapy for STEMI, clopidogrel 
pretreatment hours to days before PCI is superior to Clopido-
grel treatment initiated at the time of PCI in preventing major 
adverse cardiovascular events.
The COMMIT trial enrolled nearly 46,000 patients who 
presented within 24 hours after the onset of a suspected acute 
MI and were randomly assigned to receive clopidogrel (75 
mg daily) or placebo in addition to aspirin. Treatment was to 
continue until discharge or up to 4 weeks in hospital (mean 15 
days in survivors). The study was done exclusively in China, 
there was no upper age limit (26% of patients aged 70 years or 
older), and the average time from symptom onset to presenta-
tion was a little over 10 hours. Only half of patients received 
fibrinolytic therapy on presentation (urokinase), and clopido-
grel was administered as 75 mg daily, without a loading dose. 
Fewer than 5% of patients went on to have PCI. COMMIT 
addressed the net effects on mortality and major morbidity of 
adding clopidogrel to aspirin in the setting of STEMI.
Despite differences regarding the design, setting and 
participants in the PCI-CLARITY and COMMIT, both 
trials concluded that clopidogrel effectively reduces the 
incidence of major adverse cardiovascular events without a 
significant increase in major or minor bleeding. These effects 
were consistent across a very wide range of patient subgroups 
and independent of other pharmacological or interventional 
treatments being used. Surprisingly, some of the clinical ben-
efit of clopidogrel does emerge rapidly within a few hours 
after administering even a single dose as low as 75 mg orally, 
although loading doses of ≥ 300 could produce even greater 
antiplatelet effects more rapidly. Indeed, in the COMMIT 
trial, clopidogrel 75 mg once daily reduced the rate of death, 
reinfarction, or stroke by 12% within the first 12 hours (P = 
0.05), by 11% within the first day (P = 0.01), and by 9% (P 
= 0.002) among patients treated for 2 weeks; while in the 
PCI-CLARITY trial, pretreatment with clopidogrel (300-mg 
loading dose followed by 75 mg once daily) reduced the rate 
of reinfarction or stroke over a median 3.5-day period prior to 
PCI by 35% (P = 0.03), and the incidence of cardiovascular 
death, reinfarction, or stroke from PCI trough 30 days by 42% 
(P = 0.008). As regards the effect on mortality, a clopidogrel 
treatment, even as 75 mg once daily, initiated at the time of 
presentation seems to reduce the short-term mortality after 
acute STEMI regardless of other treatments [2]; and the 
clopidogrel pretreatment hours to days before PCI strongly 
trends to reduce the incidence of cardiovascular death after 
elective PCI for STEMI initially treated with fibrinolytics 
and aspirin [1].
Accordingly, these data add further support to the early 
use of clopidogrel in STEMI and to the broader strategy of 
clopidogrel pretreatment in patients undergoing to PCI.
The CHARISMA [3] trial tested the hypothesis that long-
term treatment with a combination of clopidogrel plus aspirin 
may provide greater protection against cardiovascular events 
than aspirin alone in a broad population of patients at high 
risk. This study enrolled nearly 15,600 patients with either 
clinically evident cardiovascular disease or multiple risk fac-
tors. These patients were randomly assigned to receive clopi-
dogrel (75 mg per day) plus low-dose aspirin (75 to 162 mg 
per day) or placebo plus low-dose aspirin and were followed 
for a median of 28 months. The primary efficacy end point 
was a composite of MI, stroke, or death from cardiovascular 
causes. The secondary efficacy end point was a composite 
of primary, or hospitalization for unstable angina, transient 
ischemic attack, or revascularization.
As regards the whole study population of patients with 
stable cardiovascular disease or multiple cardiovascular risk 
factors, the combination of clopidogrel plus aspirin was not 
significantly more effective than aspirin alone in reducing the 
rate of the primary efficacy end point. There was a moderate, 
though significant, reduction in the secondary composite end 
point (absolute reduction 1.2%, relative reduction by 6.7%; P 
= 0.04), but it mainly was due to the reduction of hospitaliza-
tions (absolute reduction 1.2%, relative reduction by 10; P = 
0.02). Moreover, a strong trend prompting concern was noted 
regarding severe bleeding (increase by 30%, P = 0.09), and 
the rate of moderate bleeding was significantly greater with 
clopidogrel than with placebo. Finally, a total of 94 secondary 
ischemic end points (mainly hospitalizations) were prevented 
with clopidogrel, at a cost of 93 moderate or severe bleeding 
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events.
As regards the subpopulation of patients with symptomatic 
but stable atherosclerotic disease, clopidogrel was associated 
with a marginally significant increase in the rate of primary 
efficacy end point, but it had no effect on death from cardio-
vascular causes. Moreover, clopidogrel increased the risk of 
moderate or severe bleeding in this subgroup, although there 
was no significant increase in intracranial or fatal bleeding.
On the other hand, long-term dual antiplatelet therapy 
in the subpopulation of asymptomatic patients with multiple 
cardiovascular risk factors was associated with surprisedly 
unexpected results. Although the difference by 20% in the 
rates of primary end point between clopidogrel and placebo 
was not significant, there were excess fatalities and a height-
ened risk of bleeding. Specifically, clopidogrel use was associ-
ated with a significant increase in the rate of death from all 
causes (nearly by 30%, P = 0.04) as well as in the rate of death 
from cardiovascular causes (by 44%, P = 0.01). At present, 
there is no reasonable and convincing interpretation of this 
unexpected finding.
In conclusion, the combination of clopidogrel plus aspi-
rin was not significantly more effective than aspirin alone in 
reducing the rate of myocardial infarction, stroke, or death 
from cardiovascular causes among patients with stable car-
diovascular disease or multiple cardiovascular risk factors. 
Furthermore, the risk of moderate-to-severe bleeding was 
increased. CHARISMA trial does not support the use of 
dual antiplatelet therapy across the broad population tested. 
There was a potential benefit in symptomatic patients with 
established vascular disease. However, whether dual anti-
platelet therapy is beneficial in more specific subgroups of 
the population of patients with atherothrombotic disease or 
risk requires further study. Moreover, data on mortality rates 
suggest that dual antiplatelet therapy should not be used in 
patients without a history of established vascular disease. 
So far, the incremental value of long-term dual antiplateled 
therapy has been validated only in the settings of coronary 
stenting and non-STE ACS for a mid-term period up to 9 to 
12 months. If anything, a subgroup analysis could be used to 
generate a hypothesis for future studies to help define the 
currently blurry distinction between the benefits and risks 
of dual antiplatelet therapy in patients with acute injury and 
those in patients with more stable vascular disease.
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